肿瘤防治研究2017，Vol.44Issue(4)：281-285,5.DOI:10.3971/j.issn.1000-8578.2017.04.009
雷替曲塞为基础化疗方案治疗晚期原发性肝癌的临床观察
Clinical Observation of Raltitrexed-based Regimen for Advanced Primary Liver Carcinoma
柯雯 1华海清 1秦叔逵 1曲文书 1王锋1
作者信息
- 1. 210002南京,南京中医药大学附属八一医院全军肿瘤中心肿瘤内科
- 折叠
摘要
Abstract
Objective To evaluate clinical efficacy and adverse events of raltitrexed-based regimens for advanced primary liver carcinoma patients.Methods A total of 31 advanced primary liver carcinoma patients were treated with raltitrexed-based regimens,14 patients were the second-line treatment,10 patients were the third-line treatment and 7 patients were the fourth-line treatment.The chemotherapy regimens were irinotecan(CPY-11),oxaliplatin(AXO),gemcitabine(GEM) combined with raltitrexed respectively and single raltitrexed.The efficacy of all patients were evaluated according to Response Evaluation Criteria in Solid Tumors 1.1(RECIST 1.1).The adverse events were evaluated by Common Terminology Criteria for Adverse Events Version 4.0(NCN-CTC 4.0).Results Thirty-one patients could be evaluated.No one achieved complete response(CR) or partial response(PR),13 patients achieved stable disease(SD) and 18 patients achieved progressive disease(PD).The effective rate (CR+PR) was 0％.The disease control rate(CR+PR+SD) was 41.9％.The median time to progression(mTTP) and median overall survival(mOS) were 63 and 189 days,respectively.The main adverse events were myelosuppression and gastrointestinal reactions.These adverse events were Ⅰ ～ Ⅱ degree and well-tolerated.Conclusion Raltitrexed-based regimens for advanced primary liver carcinoma are effective and well-tolerable.It may lengthen the overall survival and is worthy of further study.关键词
原发性肝癌/系统化疗/雷替曲塞Key words
Primary liver carcinoma/Systemic chemotherapy/Raltitrexed分类
医药卫生引用本文复制引用
柯雯,华海清,秦叔逵,曲文书,王锋..雷替曲塞为基础化疗方案治疗晚期原发性肝癌的临床观察[J].肿瘤防治研究,2017,44(4):281-285,5.
